591 likes | 1.12k Views
Endometriosis. The Disease Definitions and Epidemiology Aetiology Symptomatology. Diagnosis Laparoscopy Laparoscopic Images The Outlook. Endometriosis (continued). Treatment Current Treatment Options Non-specific Therapies Specific Therapies Progestins Danazol GnRH Agonists
E N D
Endometriosis • The Disease • Definitions and Epidemiology • Aetiology • Symptomatology • Diagnosis • Laparoscopy • Laparoscopic Images • The Outlook
Endometriosis (continued) • Treatment • Current Treatment Options • Non-specific Therapies • Specific Therapies • Progestins • Danazol • GnRH Agonists • Surgery • Guidelines • Summary
Endometriosis: The Disease Definitions and Epidemiology
Definitions • ‘The presence of endometrial-like tissue outside the uterus… induces a chronic, inflammatory reaction’1 • Endometriosis: derived from ancient Greek:endo - ‘inside’ and metra - ‘womb’ • ‘…found predominantly in women of reproductive age, from all ethnic and social groups’1 • ‘…associated symptoms can impact on general physical, mental and social well-being’1 • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.
Epidemiology • Endometriosis is a prevalent condition: • 5–10% of the female population1,2 • ~5.5 million women in USA; ~16 million in Europe3 • Affects women during reproductive years • Younger age at onset predicts more severe disease4 • ~50% in women with dysmenorrhea; 75% in women with pelvic pain; 25–40% in infertile/subfertile women5,6 • Mounsey AL et al. Am Fam Phys 2006; • Eskenazi B & Warner ML. Obstet Gynecol Clin North Am 1997; • Taylor MM AORN 2003; • Ballweg ML et al. J Pediatr Adolesc Gynecol 2003; • Child TJ et al. Drugs 2001; • Cramer DW et al. Ann N Y Acad Sci 2002.
Endometriosis: The Disease Aetiology
Sites Commonly Affected • ‘Extent of disease varies from a few, small lesions on otherwise normal pelvic organs to large, ovarian endometriotic cysts (endometriomas),and/or extensive fibrosis and adhesion formation causing markeddistortion of pelvic anatomy’1 • Pelvic cavity: • Peritoneum, ovaries,pouch of Douglas,uterosacral ligaments • Other sites: • Vagina, bowel, bladder, ureters • Rare sites: • Lungs, brain • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.
Critical Aspects of Pathogenesis • Endometrial-like cells attach to peritoneal tissue/other sites • Cellular infiltration/invasion, involving angiogenesis • Cellular proliferation • Inflammation which can cause • Nerve irritation • Adhesions • Individual variation Mahutte NG, Kayisli U, Arici A. Endometriosis in Clinical Practice. 2005; Fraser IS. J Hum Reprod Sci 2008.
Risk Factors • Pathophysiology unclear • Certain characteristics lead to increased/decreased risk • Mounsey AL et al. Am Fam Phys 2006; • Missmer SA et al. Obstet Gynecol 2004; • Bischoff F et al. Ann N Y Acad Sci 2004; • Eskenazi B et al. Obstet Gynecol Clin North Am 1997; • Cramer DW et al. Ann N Y Acad Sci 2002; • Hediger ML et al. Fertil Steril 2005.
Endometriosis: The Disease Symptomatology
Symptomatology • Typical symptoms: • Dysmenorrhea • Premenstrual pain • Dyspareunia • Diffuse/chronic pelvic pain • Other symptoms: • Perimenstrual symptoms(e.g. bowel- or bladder-associated) • Back pain • Chronic fatigue • Significant proportion of cases asymptomatic • Diagnosis based on symptoms alone can be difficult • Variable presentation • Similar to other conditions – irritable bowel syndrome,pelvic inflammatory disease Sinaii N, Plumb K, Cotton L et al. Fertil Steril 2008.
Prevalence and Overlap of Symptoms Pelvic pain + dysmenorrhea 25.2% Dysmenorrhea only 12.7% Pelvic pain only 6.5% Dyspareunia + pelvic pain + dysmenorrhea 34.4% Dysmenorrhea + dyspareunia 6.5% Pelvic pain + dyspareunia 3.3% Dyspareunia only 0.7% Sinaii N, Plumb K, Cotton L et al. Fertil Steril 2008. 10.7% of women did not report any gynecologic pain symptoms.
Infertility • Endometriosis is frequently associated with infertility • 30–40% experience subfertility or infertility • Lesions cause chronic inflammation/adhesions, impacting fertility • Infertility may be the sole presenting symptom • 25–40% of infertile women have endometriosis • Endometriosis may be diagnosed by chance by an infertility specialist Ozkan S, Murk W, Arici A. Ann NY Acad Sci 2008.
Natural History of Disease • Highly variable and difficult to predict in individual women • Progressive course characterised by worsening of pain1 • Younger onset age predicts more severe disease course2 • Spontaneous regression is possible3 • Koninckx PR, Meuleman C, Demeyere S et al. Fertil Steril 1991; • Ballweg J Pediatr Adolesc Gynecol 2003; • Mahmood TA, Templeton A. Hum Reprod 1990.
What is the Impact of Endometriosis? Morbidity Absenteeism Socio-economic cost Quality of life Educational opportunities Daily function Self-esteem Fertility Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; Gao X, Yeh YC, Outley J et al. Curr Med Res Opin 2006.
Diagnosis Diagnosis often delayed (average 8.3 years1) Typical clinical symptoms and signs(e.g. uterosacral nodularity)2,3 Suggestive Laparoscopic visualisation – ideally with confirmatory histology1 Magnetic resonance imaging and ultrasound4 Laboratory tests currently fail to show predictive value5,6 New semi-quantitative procedures being assessed7 Definitive New techniques • Kennedy S, Bergqvist A, Chapron C, et al. Hum Reprod 2005; • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Matorras R, Rodríguez F, Pijoan JI, et al. Am J Obstet Gynecol 1996; • Bazot et al. J Minim Invasive Gynecol 2005; • Bedawy et al. Clin Chem Acta 2004; • Matalliotakis et al. Arch Gynecol Obstet 2005; • Fraser et al. J Hum Reprod Sci 2008.
Diagnostic Pathway Clinical presentation: typical symptoms Endometriosis suspected History Examination Investigations Consider differential diagnoses Likely diagnosis of endometriosis –management considerations
Typical Symptoms • Dysmenorrhea • Most commonly reported symptom • Severe form highly suggestive of endometriosis1 • Dyspareunia • Commonly found in peritoneal (88%) and rectovaginal (100%) disease2 • No relationship between stage and site of disease • Normal clinical examination cannot exclude endometriosis3–5 • Mahmood TA, Templeton A. Hum Reprod 1991; • Gruppo Italiano per lo Studio dell’Endometriosis. Hum Reprod 2001. 3. Koninckx PR, Meuleman C, Oosterlynck D et al. Fertil Steril 1996; 4. Chapron C, Dubuisson JB, Pansini V et al. Fertil Steril 2002; 5. Eskenazi B, Warner M, Bonsignore L et al. Fertil Steril 2001.
Endometriosis: Diagnosis Laparoscopy
Laparoscopy: Advantages and disadvantages • Kennedy S, Bergqvist A, Chapron C et al. Hum Reprod 2005; • Brosens IA, Brosens JJ. Eur J Obstet Gynecol Reprod Biol 2000; • Al-Jefout M, Dezarnaulds G, Cooper M et al. Hum Reprod 2009.
Laparoscopic Findings • Lesions1 • ‘Powderburn’/‘gunshot’ lesions on ovaries, serosal surfaces, peritoneum • Black, dark-brown or bluish puckered lesions, nodules or small cystscontaining old hemorrhage surrounded by variable extent of fibrosis • Atypical or ‘subtle’ lesions – implants (petechial, vesicular, polypoid, hemorrhagic, red flame-like), serous/clear vesicles • White plaques/scarring, yellow-brown discoloration of peritoneum • Endometriomas (‘chocolate cysts’)1 • Contain thick tar-like fluid • Deeply infiltrating endometriotic nodules1 • Extend >5 mm beneath peritoneum • May involve uterosacral ligaments, vagina, bowel, bladder or ureters • Depth of infiltration related to type and severity of symptoms • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod. 2005.
Laparoscopic Disease Classification (rASRM Score) rASRM, revised American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine. Fertil Steril 1997.
Laparoscopic Disease Classification (rASRM Score) • Lesion assessment based on points system at laparoscopy1 • Classification may help determine risk of infertility • No correlation between classification and symptoms2 • Revised American Society for Reproductive Medicine. Fertil Steril 1997; • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.
Endometriosis: Diagnosis Laparoscopic Images
Endometriosis: Diagnosis The Outlook
Diagnosis Non-invasive techniques remain under investigation Detection of nerve fibres in endometrial biopsy1 Biopsy Laboratory tests(e.g. serum cancer antigens CA 125, CA 19-9, serumIL-6, peritoneal fluid TNFα), fail to showpredictive value4,5 Ultrasound, computerised tomography scan or magnetic resonance imaging – may be useful adjunctive investigations2,3 Transvaginal ultrasound can detect e.g. endometriomas (but not lesions)1 Lab-based tests Imaging • Kennedy S, Bergqvist A, Chapron C, et al. Hum Reprod 2005; • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Matorras R, Rodríguez F, Pijoan JI, et al. Am J Obstet Gynecol 1996; • Bazot et al. J Minim Invasive Gynecol 2005; • Bedawy et al. Clin Chem Acta 2004; • Matalliotakis et al. Arch Gynecol Obstet 2005; • Fraser et al. J Hum Reprod Sci 2008.
Endometriosis: Treatment Current Treatment Options
Overview • No permanent cure for endometriosis • Aims of treatment (patient-dependent): • Alleviate pain and other symptoms • Reduce lesions • Maintain/restore fertility • Avoid recurrence • Improve quality of life
Individualisation of Therapy • No single approach ideal for all patients • Tailor therapy to needs and choices of patient1 • Objective of individualised therapy: • Manage complaint (pain/infertility) • Optimise balance of efficacy, safety and tolerability profiles • Enhance adherence • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.
Surgical Therapy • Aimed at removing endometrial implants and restoring fertility • Efficacy reflects the skill of the surgeon • Recurrence is common: 40–50% at 5 years1,2 • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Guo SW. Hum Reprod Update 2009.
Medical Therapy Non-specific therapies –not approved in endometriosis Including non-steroidalanti-inflammatory drugs and combined oral contraceptives Specific therapies –approved in endometriosis e.g. gonadotropin-releasinghormone agonists, danazol and some progestins
Treatment Approach • ‘Endometriosis should be viewed as a chronic disease that requires a life-long management plan with the goal of maximising the use of medical treatment andavoiding repeated surgical procedures’ Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2008.
NSAIDs • General, non-specific pain relief • Controlled trial data lacking1,2 • No single NSAID shows superior efficacy1 • Potential adverse effects in gastrointestinal tract1,2 NSAID, non-steroidal anti-inflammatory drug. • Allen C, Hopewell S, Prentice A. Cochrane Database Syst Rev 2005; • Kennedy S et al. Hum Reprod 2005.
Combined Oral Contraceptives • Combined oral contraceptives are widely used off-label for endometriosis • Lack of randomised controlled trials1,2 • Limited guidance on optimal regimens • Estrogen in oral contraceptives appears counter-productive for endometriosis treatment2 • Hormonal therapies indicated for endometriosis counteract estrogen effects on endometrial tissue • Estrogenic adverse effects (nausea, weight gain, water retention, increased thromboembolic risk)1 • Davis LJ, Kennedy SS, Moore J et al. Cochrane Database Syst Rev 2007; • Crosignani P, Olive D, Bergqvist A et al. Hum Reprod Update 2006.
Endometriosis: Medical therapy Specific Therapies
Hormonal Therapy* GnRH agonists (suppression of FSH/LH via desensitisation and down-regulation of pituitary GnRH receptors) • Leuprolin • Goserelin • Buserelin • Triptorelin • Nafarelin • Avorelin Progestins / antiprogestin (suppression of FSH/LH, some have additional properties, e.g. anti-inflammatoric) • MPA (oral/im/sc) • Dydrogesterone • Norethisterone • Dienogest • Gestrinone Androgens (suppression of FSH/LH, anti-estrogenic and hyperandrogenism) • Danazol * Not all products are available in all countries. FSH, follicle stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; MPA, medroxyprogesterone acetate Vercellini et al. Best Pract Res Clin Obstet Gynaecol 2008; Mihalyi et al. Expert Opin Emerg Drugs 2006.
Progestins • Synthetic hormones with progesterone-like activity1,2 • First used to treat endometriosis in the 1950s3, most have not been developed for the treatment of endometriosis • Derived from different steroids (e.g. progesterone, testosterone),differ in their actions • Limited evidence from controlled (especially placebo-controlled) trials, scarcity of data also hampers the selection of one progestin over another • Adverse events include irregular bleeding and (especially with older agents) weight gain, headaches, acne and adverse lipid changes4,5 • Newer types selectively bind progesterone receptors specifically to minimise androgenic, estrogenic or glucocorticoid side-effects1 • Sitruk-Ware R. Hum Reprod Update 2006; • Schindler AE et al. Maturitas 2003; • Kistner RW. Am J Obstet Gynecol 1958; • Winkel CA & Scialli AR. J Womens Health Gend Based Med 2002; • Vercellini P et al. Hum Reprod Update 2003.
GnRH Agonists • Synthetic peptides modelled on hypothalamic GnRH • Mechanism of action: down-regulation of pituitary gonadotropin secretion, inducing a hypoestrogenic anovulatory state1,2 • Considered ‘standard’ treatment for endometriosis due to high efficacy1–4 • Hypoestrogenic side-effects, including BMD decrease • Limited to short-term use (6 months) in absence of ‘add-back’ therapy • ‘Add-back’ therapy adds to expense; optimal regimens not established • Caution in younger women not reached maximum BMD GnRH, gonadotropin-releasing hormone; BMD, bone mineral density. • Winkel CA et al. J Women’s Health Gender-Based Med 2001; • Sinaii N et al. Fertil Steril 2007; • Crosignani P et al. Hum Reprod Update 2006; • Mounsey AL et al. Am Fam Phys 2006.
Endometriosis: Surgical therapy Surgery
Surgical Treatment • Usually performed as laparoscopy in one procedure combining diagnosis and treatment • Surgical intervention includes: excision or ablation of endometriotic lesions, removal of endometriotic cysts, adhesiolysis1 • Frequently combined with follow up medical therapy • Preferred approach in infertile patients2 • Role in pain relief unclear2 • Success reflects the skill of practitioner • Recurrence of endometriosis is common –5-year recurrence rate approximately 40–50%3 • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Jacobson TZ et al. Cochrane Database 2008; • Guo SW. Hum Reprod Update 2009.